<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935725</url>
  </required_header>
  <id_info>
    <org_study_id>AUT021206</org_study_id>
    <secondary_id>2016-000216-14</secondary_id>
    <nct_id>NCT02935725</nct_id>
  </id_info>
  <brief_title>A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males</brief_title>
  <official_title>A Phase 1, Single-centre, Double-blind, Placebocontrolled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autifony Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Autifony Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the
      pharmacoMRI Effects of AUT00206 in Healthy Male Participants
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant difference in BOLD phMRI signals after dosing with AUT00206 vs placebo</measure>
    <time_frame>15 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Low dose AUT00206 800 mg + Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose AUT00206 (800 mg) + ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose AUT00206 2000 mg + Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose AUT00206 (2000 mg) + ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Ketamine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose AUT00206 800mg</intervention_name>
    <arm_group_label>Low dose AUT00206 800 mg + Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose AUT00206 2000 mg</intervention_name>
    <arm_group_label>High dose AUT00206 2000 mg + Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Ketamine</arm_group_label>
    <arm_group_label>Placebo + Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>Low dose AUT00206 800 mg + Ketamine</arm_group_label>
    <arm_group_label>High dose AUT00206 2000 mg + Ketamine</arm_group_label>
    <arm_group_label>Placebo + Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Placebo + Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 18 to 45 years, inclusive at Visit 1.

          -  Healthy on the basis of medical history, psychiatric history, physical examination,
             vital signs, 12-lead electrocardiogram (ECG), haematology, blood chemistry and
             urinalysis within 6 weeks of Visit 2.

          -  Right-handed.

          -  Not a regular smoker (maximum 5 cigarettes per week or equivalent).

        Exclusion Criteria:

          -  History of, or current condition of, migraine headaches or has undergone operations to
             the head.

          -  History of significant claustrophobia.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bill Deakin, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Manchester</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made publicly available on completion of the trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

